MRI Gadolinium-Based Contrast Media : Meeting Radiological, Clinical, and Environmental Needs
Bendszus, Martin (Heidelberg University Hospital (Alemanya))
Laghi, Andrea (Sant'Andrea University Hospital)
Munuera, Josep (Institut de Recerca Sant Pau)
Tanenbaum, Lawrence N. (RadNet Inc.)
Taouli, Bachir (Icahn School of Medicine at Mount Sinai (Nova York, Estats Units d'Amèrica))
Thoeny, Harriet C. (University of Fribourg)

Fecha:	2024
Resumen:	Gadolinium-based contrast agents (GBCAs) are routinely used in magnetic resonance imaging (MRI). They are essential for choosing the most appropriate medical or surgical strategy for patients with serious pathologies, particularly in oncologic, inflammatory, and cardiovascular diseases. However, GBCAs have been associated with an increased risk of nephrogenic systemic fibrosis in patients with renal failure, as well as the possibility of deposition in the brain, bones, and other organs, even in patients with normal renal function. Research is underway to reduce the quantity of gadolinium injected, without compromising image quality and diagnosis. The next generation of GBCAs will enable a reduction in the gadolinium dose administered. Gadopiclenol is the first of this new generation of GBCAs, with high relaxivity, thus having the potential to reduce the gadolinium dose while maintaining good in vivo stability due to its macrocyclic structure. High-stability and high-relaxivity GBCAs will be one of the solutions for reducing the dose of gadolinium to be administered in clinical practice, while the development of new technologies, including optimization of MRI acquisitions, new contrast mechanisms, and artificial intelligence may help reduce the need for GBCAs. Future solutions may involve a combination of next-generation GBCAs and image-processing techniques to optimize diagnosis and treatment planning while minimizing exposure to gadolinium. Level of Evidence: 5. Technical Efficacy: Stage 3.
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Lengua:	Anglès
Documento:	Article de revisió ; recerca ; Versió publicada
Materia:	Gadolinium-based contrast agents ; Gadopiclenol ; Magnetic resonance imaging
Publicado en:	Journal of Magnetic Resonance Imaging, Vol. 60 Núm. 5 (november 2024) , p. 1774-1785, ISSN 1522-2586

DOI: 10.1002/jmri.29181
PMID: 38226697

12 p, 692.6 KB

El registro aparece en las colecciones:
Documentos de investigación > Documentos de los grupos de investigación de la UAB > Centros y grupos de investigación (producción científica) > Ciencias de la salud y biociencias > Institut de Recerca Sant Pau
Artículos > Artículos de investigación
Artículos > Artículos publicados